Back Pain in Patients With Severe Osteoporosis
Back Pain in Patients With Severe Osteoporosis
The purpose of this study is to compare the effectiveness of teriparatide versus therapies
 that decrease bone loss to prevent new or worsening back pain in patients with osteoporosis
 seen in clinical practice.
Study B3D-CR-B013 is a prospective observational study to compare changes in back pain among
 patients treated with teriparatide versus those treated with antiresorptives (raloxifene,
 daily or weekly bisphosphonates).
Inclusion Criteria:

 -  Men and postmenopausal women who have a previous vertebral osteoporotic fracture that
 was sustained at least 6 weeks prior to joining the study.

 -  Patients who are free of severe or chronically disabling conditions other than
 osteoporosis.

 -  Patients who are not currently receiving and have not previously received
 teriparatide.

 -  Patients who agree to participate, return to follow-up visits, and who have signed
 informed consent to participate in the study.

 -  Patients, who in the opinion of the prescribing physician, are eligible to receive the
 intended treatment and comply with all the recommendations stated in the relevant
 product information.

 Exclusion Criteria:

 -  Are investigator site personnel directly affiliated with the study and/or their
 immediate families. Immediate family is defined as a spouse, parent, child, or
 sibling, whether biological or legally adopted.

 -  Are Lilly employees (that is, employees, temporary contract workers, or designees
 responsible for conducting the study). Immediate family of Lilly employees may
 participate in Lilly-sponsored clinical trials, but are not permitted to participate
 at a Lilly facility.

 -  Patients who have any contraindications according to the relevant product information
 in the country in which they are being treated.

 -  Patients who are simultaneously participating in a different study that includes a
 treatment intervention and/or an investigational drug.